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 2
Abstract 20 
 21 
Insulinomas (INS) are the most common neuroendocrine pancreatic tumours in humans and 22 
dogs. The long-term prognosis for malignant INS is still poor due to a low success rate of the 23 
current treatment modalities, particularly chemotherapy. A better understanding of the 24 
molecular processes underlying the development and progression of INS is required to 25 
develop novel targeted therapies. Cancer stem cells (CSCs) are thought to be critical for the 26 
engraftment and chemoresistance of many tumours, including INS. This study was aimed to 27 
characterise and target INS CSCs in order to develop novel targeted therapies.  28 
Highly invasive and tumourigenic human and canine INS CSC-like cells were successfully 29 
isolated. These cells expressed stem cell markers (OCT4, SOX9, SOX2, CD133 and CD34), 30 
exhibited greater resistance to 5-fluorouracil (5-FU), and demonstrated a more invasive and 31 
tumourigenic phenotype in vivo compared to bulk INS cells. Here, we demonstrated that 32 
Notch-signalling-related genes (NOTCH2 and HES1) were overexpressed in INS CSC-like 33 
cells. Protein analysis showed an active NOTCH2-HES1 signalling in INS cell lines, especially 34 
in cells resistant to 5-FU. Inhibition of the Notch pathway, using a gamma secretase inhibitor 35 
(GSI), enhanced the sensitivity of INS CSC-like cells to 5-FU. When used in combination GSI 36 
and 5-FU, the clonogenicity in vitro and the tumourigenicity in vivo of INS CSC-like cells were 37 
significantly reduced. These findings suggested that the combined strategy of Notch 38 
signalling inhibition and 5-FU synergistically attenuated enriched INS CSC populations, 39 
providing a rationale for future therapeutic exploitation.  40 
  41 
42 
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Introduction 43 
 44 
Insulinomas (INS) are the most common functioning neuroendocrine pancreatic tumours 45 
(PancNETs) in humans and dogs. INS are insulin-producing tumours that arise from beta-46 
cells (Wang et al. 2004; Bailey et al. 2007; Polton et al. 2007; Athanasopoulos et al. 2011; 47 
Baudin et al. 2014; Buishand et al. 2014). The treatment of choice for localised benign INS is 48 
surgical resection (Bailey et al. 2007; Buishand et al. 2014). However, for advanced stage 49 
disease medical treatment options for adjuvant therapy are limited. Combinations of 50 
chemotherapies such as streptozocin plus 5-fluorouracil (5-FU) or doxorubicin have been 51 
used in these cases, but response rates, are variable and generally disappointing (Corroller 52 
et al. 2008; Mathur et al. 2012). Thus, effective new treatment strategies are required.  53 
We hypothesise that the malignant behaviour and recurrence of INS is driven by a 54 
subpopulation of cancer stem cells (CSCs). CSCs are unique subpopulations of the 55 
heterogeneous cell population of a tumour, which are considered to be responsible for 56 
tumour initiation, metastasis, and recurrence (Mitra et al. 2015). CSCs have been described 57 
to be able to resist systemic anti-cancer treatment by several mechanisms including entering 58 
into a quiescence state; up-regulation of expression of xenobiotic efflux pumps; and 59 
enhancing anti-apoptotic and DNA repair pathways to allow cell survival (Bomken et al. 60 
2010). Therefore, CSCs are able to survive and initiate tumour relapse after systemic 61 
treatment, making them an essential target for novel anti-cancer drugs. 62 
Despite the growing evidence to support the existence of CSCs in a wide array of solid 63 
tumours, a comprehensive characterisation of INS CSCs has not yet been reported (Grande 64 
et al. 2011). Previous studies have already identified pancreatic cells with a stem cell 65 
phenotype in human and canine INS (Ordonez, 2001; Buishand et al. 2013). These so-called 66 
amphicrine cells co-express both endocrine and exocrine markers (Ordonez, 2001). 67 
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Furthermore, recent studies have identified CD90 as a potential marker for CSCs in a human 68 
INS cell line (Buishand et al. 2016). However, there are no consensus markers available to 69 
identify INS CSC-like cells and additionally, recent studies show that several CSC 70 
populations may reside within one tumour (Hou et al. 2014; Krampitz et al. 2016).  71 
The lack of knowledge regarding CSCs in INS can be partly attributed to the low incidence of 72 
human INS. With only four cases per million population per year, the availability of research 73 
material is limited, especially for malignant subtypes (Callacondo et al. 2013). Previously, 74 
investigators have analysed changes in gene expression of malignant INS mainly as part of 75 
broad studies on PancNETs (Speel et al. 1999; Zhao et al. 2001). However, PancNETs 76 
represent a heterogeneous group of tumours and therefore, the specific tumourigenesis of 77 
INS is still poorly understood. The incidence of canine INS has not been specified yet but it is 78 
higher compared to humans. Data collected at the Department of Clinical Sciences of 79 
Companion Animals of Utrecht University have recorded 10 referral cases of malignant 80 
canine INS on a yearly basis, out of a total of two million dogs in The Netherlands (FO 81 
Buishand, unpublished observations). This provides readily available canine INS samples for 82 
molecular studies.  83 
Canine INS are classified as malignant tumours in 95% of the cases as they often 84 
metastasise to abdominal lymph nodes and liver (Buishand et al. 2010). As in humans, 85 
canine patients diagnosed with malignant INS are often presented with relapse of 86 
hyperinsulinaemia due to the outgrowth of micrometastases that were not detected at the 87 
time of initial surgery (Jonkers et al. 2007; Goutal et al. 2012). From a comparative oncology 88 
perspective, which aims to utilise spontaneous tumours in pet animals as natural models for 89 
the study of human cancer biology and therapy (Gordon et al. 2009), the close resemblance 90 
of canine INS to human malignant INS, makes canine INS an interesting study model for 91 
human malignant INS. The major benefit of comparing human INS cells to canine INS cells 92 
Page 4 of 40
 5
instead of murine cells from genetically-induced INS mouse models (Schiffman et al. 2015) is 93 
that spontaneous canine tumour cells are more representative of the complex heterogeneity 94 
of INS, as they are not induced by a set of specific mutations, but arise spontaneously in a 95 
dog. Therefore, the translational gap between pre-clinical in vitro studies and the application 96 
of novel drugs in a clinical setting can be overcome by using naturally occurring canine INS 97 
as model for human INS (Gordon et al. 2009).  98 
Using a comparative oncology approach, the first goal of this study was to isolate and 99 
characterise human and canine enriched INS CSC populations. As CSCs are known to often 100 
co-opt stem and progenitor cell properties, we have used the potential functional 101 
conservation of stem cell-surface and intrinsic enzymatic markers found on self-renewing 102 
cells to identify and characterise tumourigenic cells. We then set out to identify therapeutic 103 
targets in signalling pathways in INS, performing gene expression profiling of adherent INS 104 
cells and CSC-enriched tumourspheres. We showed that the Notch pathway is a critical 105 
pathway involved in INS CSC viability. Using both in vitro and in vivo models, we have 106 
demonstrated the efficacy of targeting the Notch pathway in decreasing INS CSC survival 107 
and resistance to 5-FU, thereby providing preclinical evidence that adjuvant anti-Notch 108 
therapy may improve outcomes for patients with malignant INS. 109 
  110 
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Materials and Methods 111 
 112 
Cell culture 113 
The human INS cell line CM (Baroni et al. 1999) was cultured in RPMI-1640 (Roswell Park 114 
Memorial Institute Media, Invitrogen, Life Technologies, Paisley, UK) supplemented with 10% 115 
foetal bovine serum (FBS) (Invitrogen) and 1% penicillin-streptomycin and plasmocin 116 
(Invitrogen). The canine INS cell line canINS was derived from a primary canine INS, TNM 117 
stage II (Buishand et al. 2010), resected from a 6-year old male Flatcoated Retriever at the 118 
Faculty of Veterinary Medicine, Utrecht University. Using an insulin radioimmunoassay 119 
(Cisbio, Codolet, France), it was determined that the first passage of canINS produced 305 120 
µU/L insulin, however insulin secretion was lost after the fourth passage, like in the CM cell 121 
line. Further details on the characterisation of canINS can be found in the Supplementary 122 
data 1 (Fig. S1-2). canINS was cultured in RPMI-1640 supplemented with 10% FBS, 1% 123 
penicillin-streptomycin, 200ng/mL growth hormone (GH) (Source Biosciences, Nottingham, 124 
UK). Both lines were cultured at 37°C with 5% CO2 and cells were passaged on reaching 70-125 
80% confluence. Cell lines were authenticated using Short tandem repeat analysis (Cell 126 
Check Human 9 and Cell Check Canine; IDEXX Bioresearch, Windsor, UK). All experiments 127 
were conducted with cells from passage numbers 5-25. 128 
 129 
Tumoursphere culture 130 
Spheres were grown in serum-free medium at a density of 60,000 cells/well (2 mL volume) in 131 
6-well low adherence plates (Corning, New York, USA). The medium consisted of 132 
DMEM/F12 (Invitrogen) supplemented with progesterone (20 nM), putrescine (100μM), 133 
sodium selenite (30 nM), transferrin (25μg/mL), insulin (20μg/mL) (Sigma-Aldrich, Dorset, 134 
UK). Every two days, human recombinant EGF (10 ng/mL) and human recombinant basic 135 
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fibroblast growth factor (bFGF) (10 ng/mL) (Peprotech, London, UK) were added. Spheres 136 
were passaged every week up until 15 passages. All experiments were conducted in 137 
triplicate.  138 
 139 
RNA extraction and quantitative real time PCR 140 
Total cellular RNA was extracted using RNeasy® kit (Qiagen, Redwood City, CA, USA) and 141 
was reverse transcribed using the OmniscriptTM RT Kit (Qiagen) according to the 142 
manufacturer’s instructions. Quantitative real time PCR (qRT-PCR) was performed for genes 143 
of interest by using the Stratagene M63000p qPCR system (Agilent, Santa Clara, CA, USA), 144 
and the PlatinumH SYBRH Green qPCR SuperMix-UDG (Invitrogen) according to 145 
manufacturer’s instructions (primers are listed in Supplementary Tables 1 and 2). Relative 146 
gene expression levels were obtained by normalisation to the expression levels of 147 
housekeeping gene GADPH. Calculations were made using the Delta Delta Ct Method. 148 
 149 
Protein extraction and western blotting 150 
Cells were lysed in urea lysis buffer (7 M urea, 0.1 M DTT, 0.05% Triton X-100, 25 mM NaCl, 151 
20 mM Hepes pH 7.5). Then cells were transferred to 0.1 mL Bioruptor®Microtubes 152 
(Diagenode, Seraing, Belgium) and sonicated using pre-chilled Bioruptor® Pico sonicator 153 
(Diagenode) following the manufacturer’s instructions. Equal amounts of protein were 154 
separated by SDS polyacrylamide gel electrophoresis (SDS PAGE), transferred to Hybond-C 155 
nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK) and 156 
hybridised to the appropriate primary antibody and HRP-conjugated secondary antibody for 157 
subsequent detection by ECL. Antibodies used against HES1 (EPR4226) (1:600), Beta actin 158 
(AC-15) (1:5000), SOX9 (ab26414) (1:500) and OCT4 (ab18976) (1:1000) were purchased 159 
from Abcam (UK). Secondary antibodies were obtained from Dako (Glostrup, Denmark) 160 
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(Goat anti-Rabbit-HRP; Rabbit anti-Mouse-HRP). The appropriate secondary antibody was 161 
diluted 1:1000 (Rabbit anti-Mouse-HRP) or 1:2000 (Goat anti-Rabbit-HRP). 162 
 163 
Choriollantoic membrane assay 164 
Fertilised ISA Brown layer strain chicken eggs (Roslin Institute Poultry Unit, UK) were 165 
incubated in a humidified rotary incubator (Brinsea Octagon 40 OX incubator) at 37oC. As 166 
chick embryo chorioallantoic membrane experimental protocols were conducted and 167 
concluded during the first two-thirds of the incubation of the embryonated eggs, according to 168 
the UK Animals (Scientific Procedures) Act 1986 regulated by the Home Office, we did not 169 
require a licence (Home Office 2014).  170 
On day 7, single cell suspensions of trypsinised adherent CM and canINS cells or spheres 171 
were fluorescently labelled with PKH26 (Sigma-Aldrich, Dorset, UK) according to 172 
manufacturers’ instructions. Cells (1x104 for each condition) were suspended in a 1:1 mixture 173 
of serum-free media and Matrigel Phenol Red Free (Corning) and 25 µL was pipette-174 
inoculated directly onto the CAM. The shell windows were resealed and incubated without 175 
turning. At day 11, pictures were taken using Axio ZoomV16 coupled with AxioCAM HRM 176 
camera (Zeiss, Cambridge, UK). Images were processed using Zeiss pro image software and 177 
then the fluorescence was calculated using ImageJ 1.46 software (open source).  All data 178 
were subtracted of background fluorescence and then averaged.  179 
The embryos were decapitated and the area of the CAM inoculated with the fluorescent cells 180 
was harvested and stored in 10% neutral buffered formalin solution (Sigma-Aldrich) and 181 
embedded in an agarose block for cutting and staining. The staining was performed with anti-182 
cytokeratin (MNF116; Dako) as primary antibody at 1:50 dilution for 30 min followed by 183 
staining with secondary antibody Envision anti-Mouse HRP (Dako). Images were taken using 184 
a Nikon Eclipse Ni Brightfield Microscope and thereafter processed with Zeiss pro image 185 
software (Zeiss). 186 
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 187 
Invasion assay 188 
The invasive ability of cells was determined using the QCM™ collagen-based cell invasion 189 
assay kit (Millipore, Billerica, MA, USA) according to manufacturer’s instructions. Briefly, cells 190 
were seeded into the upper inserts at 1 × 105 cells per insert in serum-free RPMI. Cells were 191 
incubated at 37 °C with 5% CO2 for 48 hours. Non-invading cells were removed. Cells that 192 
migrated through the gel insert to the lower surface were stained and quantified by 193 
colorimetric measurement at 560 nm. Images were taken using an Eclipse Ni Brightfield 194 
Microscope (Nikon UK Ltd., Surrey, UK) and thereafter processed with Zeiss pro image 195 
software (Zeiss). 196 
 197 
Flow cytometry 198 
CM and canINS were detached by trypsinisation, washed with PBS and stained with the 199 
Zombie Violet Fixable Viability Kit (BioLegend Inc., San Diego, CA, USA) to detect dead 200 
cells. Subsequently, cells were washed again with PBS and fixed in paraformaldehyde at 1% 201 
for 10 min at 37°C and then chilled for one minute on ice. A batch of cells was also 202 
permeabilised by adding ice-cold 90% methanol slowly to pre-chilled cells under gentle 203 
vortexing. Cells were incubated for 30 min on ice, washed in incubation buffer (PBS 0.5% 204 
BSA) twice and resuspended in 100 µL of the diluted primary antibody at 1:800 dilution. After 205 
incubation with the primary antibody, cells were washed and incubated with a fluorochrome-206 
conjugated secondary antibody for 30 min. After washing with incubation buffer, cells were 207 
resuspended in PBS and analysed using BD Fortessa (BD Biosciences, Oxford, UK). The 208 
primary antibody used was monoclonal anti-rabbit Notch2 (D76A6) XP® with anti-rabbit IgG 209 
(H+L) F(abI)2 Fragment Alexa Fluor® 647 Conjugate (NewEnglandBio, Ipswich, MA, USA) as 210 
a secondary antibody. Rabbit (DA1E) mAb IgG XP® Isotype control Alexa Fluor® 647 211 
Conjugate (NewEnglandBio) was used as negative control.  212 
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 213 
Growth inhibition assays 214 
CM and canINS adherent cells and spheres were trypsinised into single cell suspensions and 215 
aliquots of 500 cells/well were seeded in triplicates in opaque 96-well plates (Corning) in 50 216 
µL medium and incubated overnight at 37°C with 5% CO2. After 24 hours serial dilutions of 5-217 
FU (Tocris, R&D System, Minneapolis, Canada), or gamma-secretase inhibitor (GSI) N-[N-218 
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) (Sigma-Aldrich) were 219 
added to the appropriate wells. Equal volumes of vehicles were used as controls. After 220 
incubation for 48 hours, cell viability was measured using the CellTiter-Glo® Luminescent 221 
Assay (Promega, Madison, WA, USA). Data of triplicate wells were averaged and normalised 222 
against the average signal of control treated samples, and dose-response curves were 223 
generated. 224 
 225 
Colony formation assays 226 
CM and canINS 2D and 3D cultures were trypsinised into single cell suspensions and seeded 227 
at 500 cells per 10 cm plate (Corning). Cells were treated with 5-FU and DAPT whilst in 228 
suspension. Plates were incubated at 37oC with 5% CO2 until colonies were visible. Growth 229 
media were changed once a week. The colonies were fixed by incubating in ice-cold 230 
methanol for 5 min at room temperature. Colonies were stained with Giemsa (Invitrogen) 231 
according to the manufacturer’s instructions. 232 
 233 
Statistical analysis 234 
All experiments were repeated at least on two separate occasions. Quantitative analysis was 235 
based on a minimum of three replicates. Data were analysed using Minitab® 17 Statistical 236 
Software (Minitab Ltd., Coventry, UK) and all graphs and diagrams were generated using 237 
Microsoft Office 2011 software (Microsoft Corporation, Redmond, WA, USA). P-values <0.05 238 
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were considered statistically significant. When data followed a normal distribution, two 239 
sample t-tests were used to compare differences between two samples, or one-sample t-240 
tests to determine whether the sample mean was statistically different from a known or 241 
hypothesised mean. IC50 values were calculated using GraphPadPrism 6 (GraphPad 242 
Software, La Jolla, CA, USA). To assess combined treatment effects on the canINS and CM 243 
cell lines, the Bliss additivism model was used (Buck et al. 2006).  244 
  245 
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Results 246 
 247 
CSC-like cells are enriched in human and canine INS spheres 248 
Human CM adherent cells (Fig. 1 A) gave rise to small and irregularly shaped spheres (Fig. 1 249 
B), whereas canine canINS adherent cells (Fig. 1 C) gave rise to well-rounded large spheres 250 
(Fig. 1 D). These cells repeatedly formed tumourspheres for up to 15 subsequent passages 251 
when plated in low-adherent conditions. To further characterise tumourspheres we examined 252 
the expression of embryonic stem cell markers OCT4 and SOX9. Both markers were 253 
expressed at a higher level in human (Fig. 1 E) and canine (Fig. 1 F) tumourspheres 254 
compared to parental adherent cells. 255 
We investigated the gene expression levels of a number of CSC-associated genes including 256 
stemness markers, stem cell surface related markers, epithelial-mesenchymal transition 257 
markers, growth factor receptors, Notch signalling pathway receptors and target genes, and 258 
pancreatic neuroendocrine and exocrine markers. CD34, CD133, OCT4, SOX2, SOX9, 259 
NOTCH2, HES1 and HEY1 were all upregulated in both human and canine INS 260 
tumourspheres compared with the adherent population (Fig. 1 G). There was no significant 261 
difference in the expression of NOTCH1, NOTCH3 and NOTCH 4 in both human and canine 262 
INS spheres, although these receptors demonstrated a trend to be downregulated in 263 
tumourspheres.  264 
 265 
INS CSC-enriched tumourspheres are highly invasive in vitro 266 
The invasive capacity of cells was tested in vitro using a collagen-based invasion assay. 267 
CSC-like cells displayed a greater invasive potential compared to the non-enriched CSCs 268 
(Fig. 2 A). When quantified, a statistically significant increased invasive potential was 269 
recorded for both human and canine INS CSC-like cells compared with non-enriched CSCs 270 
(Fig. 2 B-C).  271 
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 272 
INS CSC-enriched tumourspheres are more tumourigenic and invasive in vivo than 273 
adherent cells  274 
We developed a CAM assay protocol to monitor the tumourigenic and metastatic properties 275 
of INS cancer cells. We recorded the amount of fluorescence in triplicate CAMs for both the 276 
adherent cells and the CSC-enriched spheres and showed that the adherent INS cells did not 277 
form tumours and did not proliferate in the CAM model. However, the CSC-like populations 278 
proliferated on the CAM and gave rise to substantial tumours (Fig. 3 A-B). We quantified the 279 
red fluorescence recorded in the CAM assay and obtained a statistical significant difference 280 
for the amount of cells between the canINS adherent and CSC-like cells (Fig. 3 C). No 281 
statistical difference was recorded between both cell populations of the human INS cell line 282 
(Fig. 3 D).  283 
We then tested whether the cells were able to migrate through the deep layers of the CAM. 284 
Human and canine bulk INS cells (Fig. 4 A-B) were less invasive in vivo compared to human 285 
and canine INS CSC-like cells (Fig. 4 C-D). INS CSC-like cells demonstrated invasive 286 
behaviour moving from the outer ectoderm CAM layer through the mesoderm towards the 287 
endoderm (Fig. 4 E-F). These findings were consistent with our in vitro invasion data.   288 
 289 
INS CSC-enriched tumourspheres exhibit greater resistance to 5-FU compared with 290 
adherent cells 291 
After testing a set of chemotherapeutics commonly used in the treatment of human INS we 292 
identified 5-FU as the most suitable drug to evaluate the INS cancer cells' chemoresistance. 293 
The relative IC50 values for 5-FU of adherent CM and canINS cells were 5 µM and 0.5 µM, 294 
respectively, which reside within, or are lower than the therapeutic plasma dose range of 5-295 
FU (800 ng/mL-2000 ng/mL, 5 µM-15 µM) (Danquechin-dorval et al., 1996; Yamada, 2003; 296 
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Blaschke et al., 2012). Both CM and canINS CSC-enriched tumourspheres proved to be 297 
more resistant to 5-FU treatment compared to adherent cells in cell viability (Fig.5 A-B) and 298 
clonogenicity assays (Fig. 5 C-D).  299 
 300 
The Notch pathway is overexpressed and active in 5-FU resistant INS cells  301 
Analysis of gene expression had revealed that Notch pathway related receptor, NOTCH2, 302 
and its target gene, HES1 were upregulated in both CM and canINS CSC-enriched spheres 303 
(Fig. 1 G). Using flow cytometry, we provided evidence that the NOTCH2 receptor is 304 
constitutively activated as it is present both in its inactive form (extracellular level) and active 305 
form (intracellular level) in adherent and CSC-enriched sphere populations (Fig. 6 A-B). 306 
Using western blot analysis, we showed that both CM and canINS CSC-enriched spheres 307 
demonstrated an intrinsic higher expression of NOTCH2 and HES1 compared to the 308 
adherent INS cells. Furthermore, treatment of cells with 5-FU resulted in an increased 309 
expression of both the inactive and active form of the NOTCH2 receptor in CM (Fig. 6 C) and 310 
canINS cells (Fig. 6 D). In response to an increase in NOTCH2 expression, also its 311 
downstream target gene HES1 demonstrated an increased expression in cells that were 312 
resistant to 5-FU (Fig. 6 C-D).  313 
 314 
Inhibition of Notch signalling decreases viability and 5-FU resistance in INS CSC-315 
enriched tumourspheres  316 
Since CSC-enriched INS spheres were more resistant to 5-FU treatment compared to 317 
adherent cells and 5-FU resistant INS cells demonstrated an overexpression of active 318 
NOTCH2, we evaluated the effect of Notch pathway inhibition on INS cells. Notch 319 
inhibition using DAPT, preferentially decreased the viability of CM and canINS CSC-320 
enriched spheres (Fig. 7 A-B). CSC-enriched canINS spheres demonstrated increased 321 
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sensitivity to treatment with DAPT compared with CSC-enriched CM spheres. To confirm 322 
whether the DAPT is able to specifically inhibit the Notch pathway, we treated the human 323 
and canine cells with increasing doses of DAPT and observed, through western blot 324 
analysis, a reduced expression of the intracellular form of NOTCH2 (NOTCH2-IC) and its 325 
downstream target HES1 in both human and canine INS cell lines (Fig. 7 C-D). We 326 
demonstrated that a blockade of the Notch signalling occurs in CSC-enriched canINS 327 
spheres at a lower dose of DAPT compared to CSC-enriched CM spheres (Fig. 7 C-D). 328 
Finally, when DAPT was used in combination with 5-FU, we demonstrated that the 329 
clonogenicity of CSC-enriched CM and canINS spheres was significantly reduced. This 330 
effect was superior to use of either drug alone (Fig. 7 E-F). The synergistic effect of the 331 
combination of 5-FU and DAPT was confirmed using the Bliss independence model (Fig. 7 332 
G-H). 333 
 334 
Notch inhibition enhances chemosensitivity to 5-FU treatment of INS CSC-enriched 335 
tumourspheres in vivo  336 
In order to validate the results obtained in vitro, we tested this approach in the in vivo CAM 337 
model. Treatment with either 5-FU, DAPT, or their combination, in the CAM model 338 
demonstrated that the human and canine INS CSC populations were not able to proliferate 339 
when treated with a combination of 5-FU and DAPT (Fig. 8 A-B). We recorded the amount of 340 
fluorescence in the triplicate CAMs for the different conditions and demonstrated that the 341 
combination of 5-FU and DAPT significantly decreased the proliferation of INS CSC-like cells, 342 
while neither treatment with DAPT, or 5-FU alone led to a significant reduction in cell 343 
proliferation (Fig. 8 C-D). 344 
 345 
  346 
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Discussion 347 
 348 
In the current study, we demonstrated that human and canine INS cell lines could be 349 
enriched in CSCs by tumoursphere culturing. CSCs have been previously isolated from a 350 
variety of human (Zhu et al. 2011; Mao et al. 2014; Paschall et al. 2016; Zhao et al. 2016; 351 
Sakai et al. 2017) and canine cancer types (Wilson et al. 2008; Stoica et al. 2009; Pang et al. 352 
2011, 2012, 2017; Rybicka & Król 2016). However, to our knowledge, we are the first to 353 
report the isolation of CSC-like cells from a canine INS cell line and the use of this cell line as 354 
comparative model for human INS. 355 
CSC-enriched tumourspheres from both species demonstrated a common upregulation of 356 
stem cell-associated markers CD133, CD34, OCT4, SOX9, and SOX2. Previously, OCT4, 357 
SOX2, SOX9 and CD133 have been identified as stem cell markers of pancreatic endocrine 358 
progenitor cells (Seymour et al. 2007; Koblas et al. 2008; Wang et al. 2009; Venkatesan et al. 359 
2011). Of these markers, CD133 expression was demonstrated to be a negative 360 
prognosticator in PancNETs (Sakai et al. 2017).  361 
Human and canine CSC-like INS cells were highly invasive in vitro, similar to CSCs isolated 362 
in previous studies (Gaur et al. 2011; Pang et al. 2011; Gao et al. 2014). CSC-like INS cells 363 
displayed a greater invasive potential compared to the bulk INS cells in both in vitro invasion 364 
assays and in vivo CAM models. Previously, the CAM model has been used to model 365 
metastatic behaviour in other cancer types such as breast, bladder, prostate, ovarian cancer 366 
and head and neck cancers in humans (Deryugina et al. 2009; Lokman et al. 2012) and 367 
mammary carcinoma and osteosarcoma in companion animals (Pang et al. 2013, 2014). In 368 
our CAM assays, CSCs from INS tumourspheres developed visible tumours within 4 days, 369 
and escaped the primary inoculation site and migrated to the inner layers of the CAM. The 370 
invasive behaviour of INS CSCs in the CAM model with its highly vascularised structure, 371 
closely mimics the mode of INS metastasis which involves INS cancer cell invasion and 372 
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spread through the abdominal lymphatic system to reach the site of metastases in either 373 
lymph nodes or liver. Overall, these findings suggest CSCs may play a role in INS 374 
carcinogenesis.  375 
According to our results, INS CSC-like cells are more resistant to 5-FU compared to the 376 
adherent cancer cells. This is consistent with the CSC model stating that despite the 377 
sensitivity of bulk tumour cells to chemotherapy, CSCs are resistant and lead ultimately to 378 
the failure of cytotoxic chemotherapy, increasing the need for new CSC-targeted therapies 379 
(Guo et al. 2006). After isolating INS CSCs, we have identified the Notch pathway as a 380 
potential target for INS CSC targeted therapy. Notch signalling pathway activation occurs 381 
when a Notch receptor (NOTCH 1–4) binds to one of the five known Notch ligands (Delta-382 
like-1, -3, and -4 and Jagged-1 and -2). After receptor–ligand binding, there is a two-step 383 
proteolytic cleavage, first by ADAM10, then by gamma-secretase of the intracellular 384 
domain of the Notch receptor (NICD). NCID translocates to the nucleus, interacts with CSL 385 
transcription factors (CBF1/RBP-J, Su(H), Lag-1) which activate and promote transcription 386 
of downstream genes such as HES1, involved in various differentiation programmes 387 
(Grande et al. 2011; Abel et al. 2014). For instance, Notch signalling has a major role in 388 
pancreatic embryogenesis, influencing the balance between pancreatic endocrine 389 
progenitors, exocrine cells and differentiated beta-cells  (Angelis et al. 1999; Andersson et 390 
al. 2011). The current study demonstrates that NOTCH2 is constitutively active in CM and 391 
canINS cells. Furthermore, NOTCH2 and HES1 are overexpressed in human and canine 392 
CSC-like cells, compared to the bulk INS cells. NOTCH2 is the only Notch receptor that 393 
have demonstrated overexpression in both human and canine INS suggesting that 394 
NOTCH2 is the most relevant Notch receptor through which signalling in INS CSCs is 395 
mediated. The role of the Notch pathway has been previously described in various types 396 
of NETs (Grande et al. 2011; Carter et al. 2013; Crabtree et al. 2016) but to our knowledge 397 
this is the first study to evaluate the role of the Notch pathway in INS tumourigenicity and 398 
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in particular its role in maintaining the INS CSC population. Previous studies have 399 
identified NOTCH2 as an oncogene in NETs (Carter et al. 2013; Crabtree et al. 2016): in 400 
small cell lung carcinoma (SCLC) Notch2 signalling has shown a prominent role in tumour 401 
promotion in SCLC xenografts in mice (Crabtree et al. 2016). Recently NOTCH2 402 
overexpression has been related to increased tumourigenicity of cancer cells, and an 403 
increased resistance to 5-FU in hepatocellular carcinoma (Rui et al. 2016). In our study, 404 
we have demonstrated an increased activation of the Notch pathway in INS cells, after 405 
treatment with 5-FU. The observed enhancement in Notch signalling may be explained by 406 
a selective enrichment of the INS 5-FU resistant cells that display an active Notch 407 
signalling. In accordance with this hypothesis, previous studies have demonstrated that 408 
overexpression of HES1 has been related to an increased resistance to 5-FU in colon 409 
cancer (Candy et al. 2013) and oesophageal squamous cell carcinoma (Liu et al. 2013).  410 
Notch signalling in CM and canINS may contribute to carcinogenesis by inhibiting 411 
differentiation, promoting cellular proliferation, and/or inhibiting apoptosis, yet no studies 412 
have examined these endpoints in INS. Our results showed that NOTCH2 is constitutively 413 
activated in both CSC-like cells and bulk INS cells, although the bulk cancer cell 414 
population demonstrated a lower expression of HES1. Interestingly, Notch inhibition using 415 
DAPT preferentially decreased the viability of the CSC-like population. Considering that 416 
NOTCH2 was the only overexpressed Notch receptor in human and canine INS CSCs, 417 
these data suggest that the Notch2-Hes1 signalling cascade plays an important role in 418 
CSCs' survival and resistance to chemotherapy. Next, we have tested whether a 419 
combined regimen of DAPT and 5-FU can reverse the 5-FU resistance of INS CSC-like 420 
cells. Treatment in vitro with DAPT alone did not inhibit INS CSC-like cells clonogenicity, 421 
however, the combination of DAPT and 5-FU significantly inhibited colony-forming ability of 422 
INS CSC-like cells to a greater degree than either therapy alone. We have then used the 423 
Page 18 of 40
 19 
CAM model to study the effect of this combined treatment in vivo. The results from the 424 
CAM assay were consistent with the in vitro findings, as tumour proliferation in vivo was 425 
significantly decreased when the drugs were used in combination compared to their use 426 
as single agents. Previous studies have already shown that Notch inhibition increased the 427 
cytotoxic effects of chemotherapy in various types of cancer (Meng et al. 2009; Lee et al. 428 
2015; Li et al. 2015): for example oxaliplatin-induced activation of Notch1 signalling in 429 
metastatic colon cancer was reduced by simultaneous GSI treatment, resulting in 430 
enhanced tumour sensitivity to oxaliplatin (Meng et al. 2009); in breast cancer, combined 431 
inhibition of Notch with doxorubicin treatment resulted in decreased tumourigenicity in 432 
mouse xenograft models (Li et al. 2015); and in gastric cancer, targeting the Notch 433 
pathway significantly increased the cytotoxicity of 5-FU (Lee et al. 2015). Demonstrating 434 
that inhibition of the Notch pathway has functional consequences provides further 435 
evidence that this pathway is not only differentially expressed but plays a causative role in 436 
INS carcinogenesis.  437 
In summary, in the current study, we have isolated INS CSC-like cells from human and 438 
canine INS cell lines and have demonstrated that both subpopulations of INS CSC-like 439 
cells seem to be dependent on the Notch pathway for their survival. Furthermore, targeting 440 
the Notch pathway led to a significant increase in cytotoxicity of 5-FU in the INS CSC-like 441 
population, demonstrating a correlation between Notch activation and 5-FU resistance. 442 
The increased expression of Notch in 5-FU resistant INS cells may be clinically significant, 443 
as it provides a valuable rationale that INS patients whom developed chemoresistance 444 
might benefit from a treatment with Notch small molecule inhibitors, such as GSIs. GSI 445 
treatment has previously been used in a clinical setting to sensitise cancer cells to 446 
chemotherapy in advanced stages of solid tumours (Richter et al. 2014). Since GSIs 447 
including DAPT, inhibit cleavage of all Notch receptor families, our results may not be 448 
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exclusively due to Notch2 signalling effects. Therefore, future preclinical studies on INS 449 
will focus on the use of specific inhibitors of either NOTCH2 or HES1, and further, 450 
elucidate their potential in clinical settings.  451 
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Figure legends 1 
 2 
Figure 1 Isolation and characterisation of CM and canINS cancer stem cells (CSC).  A-B: 3 
CM in adherent (A) and in tumoursphere (B) culturing conditions (scale bar: 100 m). C-D: 4 
canINS in adherent (C) and tumoursphere (D) culturing conditions (scale bar: 100 m). E-F: 5 
Western blot analysis of CM (E) and canINS (F) stem cell markers OCT4 and SOX9 and beta 6 
actin as loading control. G: qRT-PCR of stem cell and self-renewal pathway related genes 7 
comparing CM and canINS in both adherent and sphere culturing conditions. The mRNA 8 
expression of embryonic stem cell genes (SOX9, OCT4, SOX2) and stem cell-associated 9 
surface markers (CD133, CD34) were upregulated in sphere culturing conditions. The 10 
expression of NOTCH receptor (NOTCH2) and downstream target genes (HES1, HEY1) was 11 
upregulated, whereas no significant differences were recorded in NOTCH1, NOTCH3 and 12 
NOTCH4 expression in human and canine INS spheres. Values are mean of triplicates ± SD. 13 
The P-values represent the comparison with a stated hypothesis (values >1) using one 14 
samples t-test. *P-values <0.05 were considered statistically significant. 15 
 16 
Figure 2 Invasive properties of INS CSCs in vitro. A: Representative images of invasive 17 
capacity of human (top row) and canine (bottom row) CSC-enriched spheres and adherent 18 
cells using a collagen-based cell invasion assay kit (scale bar: 20 m) B-C: Invading cells 19 
were stained and quantified by colourimetric measurement at 560 nm. Values are mean of 3 20 
± SEM.  *P-value < 0.05.   21 
 22 
Figure 3 Putative canine and human INS CSCs show an increased in vivo tumourigenic 23 
potential A: Representative photographs of the chorioallantoic membrane (CAM) 11 days 24 
after inoculation with either canINS adherent cells or CSC-enriched spheres following red 25 
fluorescent membrane labelling. Pictures on the top row show the merging of the brightfield 26 
channel; pictures on the bottom row show the red channel. A3 represents a magnified picture 27 
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of the circles shown in A2. Magnification is specified on top of each picture. B: 28 
Representative photographs of the chorioallantoic membrane (CAM) 11 days after 29 
inoculation with either CM adherent cells or CSC-enriched spheres following red membrane 30 
labelling. C3 represents magnified pictures of the circles shown in C2. C-D: Graphs show the 31 
differences in fluorescence between the two populations after quantification using ImageJ. 32 
Values are mean of 3 ± SEM.  *P-value < 0.05. 33 
 34 
Figure 4 Invasive properties of INS CSCs in vivo. A-F: Representative images of 35 
immunohistochemistry of CAM sections embedded in agar and stained with anti-cytokeratin 36 
that stains only human and canine cells (brown). The structure of CAM layers is comprised 37 
by ectoderm (ET), mesoderm (M) and endoderm (ED). Cancer cell matrigel grafts (CG) were 38 
seeded on the CAM. Pictures show the migration of CM adherent (A) and canINS adherent 39 
(B) and CM CSC-enriched sphere cells (C) and canINS CSC-enriched sphere cells (D) in the 40 
inner part of the CAM 11 days after being seeded. Results show that the CM adherent (A) 41 
and the canINS adherent (B) migrate less through the different layers of the CAM compared 42 
with the CM CSC-enriched sphere cells (C) and the canINS CSC-enriched sphere cells (D). 43 
High magnifications (20x and 60x) shows in details how the CM (E) and canINS (F) CSC-44 
enriched sphere cells disrupt the CAM membrane and invade through the CAM layers. 45 
Magnification is specified on top of each picture (scale bar: 200 m). 46 
 47 
Figure 5 Chemosensitivity and colony formation assays of CM and canINS. A-B: 48 
Chemosensitivity assay in CM (A) and canINS (B): cells were treated with increasing 49 
concentrations of 5-FU (from 0.5 to 5 µM) comparing the adherent population (dashed line) 50 
and the CSC-enriched sphere population (continuous line). C-D: Colony formation assay CM 51 
(C) and canINS (D): Human and canine cells were treated with increasing concentrations of 52 
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5-FU (from 0.5 to 5 µM) comparing the adherent population (dashed) and the CSC-enriched 53 
sphere population (solid). Values represent mean of triplicates ± SD. The P-values represent 54 
the comparison using 2 sample t-test within the adherent and the CSC-enriched spheres. *P-55 
value < 0.05 was considered statistically significant. 56 
 57 
Figure 6 Analysis of Notch pathway protein expression and activation in human and canine 58 
insulinoma (INS) cells.  A-B: Graph showing the percentage of cells positive to NOTCH2 59 
antibody using flow cytometry in human (A) and canine (B) INS cell lines. C-D: Western blot 60 
analysis of NOTCH2 in its inactive transmembrane form (NOTCH2-TM) and its active 61 
intracellular form (NOTCH2-IC), and HES1 with beta actin as a loading control in human (C) 62 
and canine (D) INS cell lines, treated with increasing doses of 5-Fluorouracil (5-FU). 63 
 64 
Figure 7 Function of the Notch pathway in canine and human insulinoma (INS) cancer stem 65 
cells (CSC). A-B: Cell viability assay of human (A) and canine (B) INS cell lines using 66 
increasing concentrations of DAPT comparing adherent cells (dashed line) against CSC-67 
enriched spheres (solid line). C-D:  Western blot analysis of NOTCH2 in its inactive 68 
transmembrane form (NOTCH2-TM) and in its active intracellular form (NOTCH2-IC), and 69 
HES1, with beta actin as a loading control in human (C) and canine (D) INS cell lines treated 70 
with increasing doses of DAPT. E-F: Colony formation assay of human (E) and canine (F) 71 
INS cell lines using a combination of DAPT and 5-fluorouracil (5-FU). Values represent mean 72 
of triplicates ± SD. The P-values represent the comparison using 2 sample t-tests within the 73 
adherent and the CSC-enriched spheres. *P-value < 0.05. G-H: Calculation of the synergistic 74 
effect of the DAPT and 5-FU using e-bliss calculation in CM (G) and canINS (H). The method 75 
compares the observed combined response with the predicted combined response. The 76 
combined effect is synergistic as it is greater than the predicted one.  77 
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 78 
Figure 8 Combined 5-FU and DAPT treatment decreases human and canine INS CSC-like 79 
cells tumourigenic potential in the in vivo chorioallantoic membrane (CAM) model. A: 80 
Representative photographs of the CAM 11 days after inoculation with CSC-enriched CM 81 
spheres following red membrane labelling. Cells have been treated with 5-FU (5 µM) and 82 
DAPT (20 µg/mL). Pictures on the top row show the merging of the brightfield channel; 83 
pictures on the bottom row show the red channel (scale bar: 100µm). B: Representative 84 
photographs of the CAM 11 days after inoculation with CSC-enriched canINS spheres 85 
following red membrane labelling. Cells have been treated with 5-FU (0.5 µM) and DAPT (20 86 
µg/ml). Pictures on the top row show the merging of the brightfield channel; pictures on the 87 
bottom row show the red channel (scale bar: 100µm). C-D: Graphs show the differences in 88 
fluorescence between the different conditions after quantification using ImageJ. Values are 89 
the mean of 3 ± SEM.  *P-value < 0.05. 90 
 91 
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